This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vertex Eyes Label Expansion of Triple Combo CF Drug in Europe
by Zacks Equity Research
Vertex's (VRTX) label expansion application Kaftrio in combination with Kalydeco gets accepted for review by the European Medicines Agency.
Novartis' Eye Drug's Safety Label Update Approved by EMA
by Zacks Equity Research
Novartis' (NVS) eye drug Beovu's safety label update receives approval from the Committee for Medicinal Products for Human Use.
Mallinckrodt Gets CRL From FDA for Terlipressin, Shares Fall
by Zacks Equity Research
Mallinckrodt (MNK) gets a Complete Response Letter from the FDA for its NDA seeking approval for terlipressin to treat adults with hepatorenal syndrome type 1.
Galapagos (GLPG) Surges: Stock Moves 8.8% Higher
by Zacks Equity Research
Galapagos (GLPG) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Immunomedics to be Acquired by Gilead for About 21 Billion
by Zacks Equity Research
Immunomedics Inc. (IMMU) will be acquired by Gilead (GILD) for about $21 billion.
Atara (ATRA) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
Atara (ATRA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Emergent Biosolutions (EBS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Emergent Biosolutions (EBS) closed at $98.08, marking a -0.93% move from the previous day.
Bayer Collaborates With Recursion for Fibrotic Diseases
by Zacks Equity Research
Bayer (BAYRY) inks deal with Recursion Pharmaceuticals for the treatment of fibrotic diseases.
Exelixis Inks a Couple of Deals to Develop Novel ADCs for Cancer
by Zacks Equity Research
Exelixis (EXEL) signs a collaboration agreement with private biotech NBE-Therapeutics for developing novel antibody-drug conjugates (ADCS) to address cancer. It also inks a similar deal with Catalent.
AVEO Acquires Full Global Rights to Ficlatuzumab From Biodesix
by Zacks Equity Research
AVEO reclaims complete rights to ficlatuzumab from Biodesix for an undisclosed sum. The candidate is being developed for several cancer indications.
Catalyst (CPRX) Eyes Firdapse Label Expansion Amid Competition
by Zacks Equity Research
Catalyst's (CPRX) efforts to expand Firdapse label are encouraging. However, with only a few candidates in the pipeline, the company's dependence on Firdapse for growth remains a matter of concern.
Gilead Submits sBLA to FDA for CAR-T in Non-Hodgkin Lymphomas
by Zacks Equity Research
Gilead submits a supplemental Biologics License Application to the FDA for Yescarta for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma.
Gilead-HiFiBiO Ink Deal to Develop Antibodies Against Leukemia
by Zacks Equity Research
Gilead's (GILD) subsidiary, Kite, enters into a two-year research deal with HiFiBiOto develop antibodies against acute myeloid leukemia.
Horizon Therapeutics' Stock Rises YTD on Approvals & Buyouts
by Zacks Equity Research
Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza, going forward in 2020. It is making efforts to expand the label for its marketed drugs.
Tenet Healthcare Offers Senior Unsecured Notes Worth $2.5B
by Zacks Equity Research
Tenet Healthcare (THC) exhibits prudence by issuing senior notes amid a low interest rate environment to procure funds.
Intercept's (ICPT) Stock Rises After Layoff Announcement
by Zacks Equity Research
Intercept (ICPT) plans to lay off its workforce to save costs and streamline operations.
RAPT Therapeutics (RAPT) Catches Eye: Stock Jumps 6.1%
by Zacks Equity Research
RAPT Therapeutics (RAPT) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Athenex's NDA for Breast Cancer Drug Gets Priority Review
by Zacks Equity Research
The FDA accepts Athenex's (ATNX) NDA for oral paclitaxel and encequidar, intended to treat metastatic breast cancer, under a priority review. The FDA's verdict is awaited on Feb 28, 2021. Stock up.
Is Emergent Biosolutions (EBS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (EBS) Outperforming Other Medical Stocks This Year?
Vertex Seeks Nod for Cystic Fibrosis Drugs for Rare Mutations
by Zacks Equity Research
Vertex's (VRTX) sNDAs seek approval of Trikafta, Symdeko, and Kalydeco for additional rare mutations in the CFTR genes.
Athenex (ATNX) Catches Eye: Stock Jumps 9.1%
by Zacks Equity Research
Athenex (ATNX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Stamps.com, Etsy, Daqo New Energy, Emergent BioSolutions and Atlas Air Worldwide
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Stamps.com, Etsy, Daqo New Energy, Emergent BioSolutions and Atlas Air Worldwide
Gilead Inks Deal With Jounce to License an Oncology Candidate
by Zacks Equity Research
Gilead (GILD) signs a deal with Jounce Therapeutics to exclusively license the latter's monoclonal antibody, JTX-1811.
Aptose Biosciences (APTO) Surges: Stock Moves 9.8% Higher
by Zacks Equity Research
Aptose Biosciences (APTO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Aimmune Set to be Acquired by Nestle for $2.6B, Stock Up
by Zacks Equity Research
Aimmune (AIMT) reaches an agreement with Nestle, S.A wherein the latter will acquire the company in an all-cash transaction worth $2.6 billion. Shares surge.